Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
The present disclosure, relates, in general to methods for improving adverse events in subjects receiving treatment with an anti-CD30 antibody drug conjugate, optionally also receiving accompanying chemotherapy. Adverse events include peripheral neuropathy and neutropenia.
1. A method for treating a hematologic cancer in a subject comprising administering to the subject a therapy comprising an anti-CD30 antibody drug conjugate and prophylactically administering to the subject a granulopoiesis stimulating factor, wherein the granulopoiesis stimulating factor is administered beginning with cycle 1 of the administration of anti-CD30 antibody drug conjugate, wherein the antibody drug conjugate comprises monomethyl auristatin E and a protease-cleavable linker consisting of a thiolreactive maleimidocaproyl spacer, a valine-citrulline dipeptide, and a p-amino-benzyloxycarbonyl spacer.
2. The method of claim 1 ,
wherein the granulopoiesis stimulating factor is administered from 1 day to 7 days after beginning with cycle 1 of the administration of anti-CD30 antibody drug conjugate, or
wherein the granulopoiesis stimulating factor is administered from 2 days to 5 days after beginning with cycle 1 of the administration of anti-CD30 antibody drug conjugate.
3. The method of claim 1 ,
wherein the granulopoiesis stimulating factor is administered from 1 day to 7 days after a second or subsequent, administration of anti-CD30 antibody drug conjugate, or
wherein the granulopoiesis stimulating factor is administered from 2 days to 5 days after the a second or subsequent administration of anti-CD30 antibody drug conjugate.
4. The method of claim 1 wherein, the granulopoiesis stimulating factor is administered 24 hours to 36 hours after each administration of anti-CD30 antibody drug conjugate.
5. The method of claim 1 wherein the granulopoiesis stimulating factor is administered to a subject that has not received anti-CD30 antibody drug conjugate therapy previously.
6. The method of claim 1 wherein the subject has not experienced treatment-emergent grade 3-4 neutropenia after anti-CD30 antibody drug conjugate administration.
7. The method of claim 1 wherein the granulopoiesis stimulating factor is a granulocyte-colony stimulating factor (GCSF).
8. The method of claim 7 wherein the GCSF is a long-acting GCSF or a non long-acting GCSF.
9. The method of claim 7 wherein
i) the GCSF is long-acting GCSF, and is administered 1 day or 2 days after beginning with cycle 1 of the administration of anti-CD30 antibody drug conjugate; or
ii) the GCSF is not long acting, and is administered 1, 2, 3, 4, 5, 6 or 7 days after beginning with cycle 1 of the administration of anti-CD30 antibody drug conjugate.
10. The method of claim 9 wherein the G-CSF is administered 24 hours to 36 hours after each administration of anti-CD30 antibody drug conjugate.
11. The method of claim 1 wherein the anti-CD30 antibody drug conjugate is administered every 3 weeks.
12. The method of claim 1 wherein the anti-CD30 antibody drug conjugate is administered every 2 weeks, optionally on day 1 and day 15 of a 28-day cycle.
13. The method of claim 1 wherein the anti-CD30 antibody drug conjugate is administered for no more than six cycles.
14. The method of claim 1 further comprising administering a chemotherapy consisting essentially of doxorubicin, vinblastine, and dacarbazine (AVD) as a combination therapy.
15. The method of claim 1 wherein the anti-CD30 antibody of the anti-CD30 antibody drug conjugate comprises
i) a heavy chain CDR1 set out in SEQ ID NO: 4, a heavy chain CDR2 set out in SEQ ID NO: 6, a heavy chain CDR3 set out in SEQ ID NO: 8; and
ii) a light chain CDR1 set out in SEQ ID NO: 12, a light chain CDR2 set out in SEQ ID NO: 14, and a light chain CDR13 set out in SEQ ID NO: 16.
16. The method of claim 15 wherein the anti-CD30 antibody of the anti-CD30 antibody drug conjugate comprises
i) an amino acid sequence at least 85% identical to a heavy chain variable region set out in SEQ ID NO: 2 and
ii) an amino acid sequence at least 85% identical to a light chain variable region set out in SEQ ID NO: 10.
17. The method of claim 1 wherein the anti-CD30 antibody of the anti-CD30 antibody drug conjugate is a monoclonal anti-CD30 antibody or a chimeric AC10 antibody.
18. The method of claim 1 wherein the anti-CD30 antibody drug conjugate is brentuximab vedotin.
19. The method of claim 1 wherein the granulopoiesis stimulating factor is administered in a dose range from 5 to 10 μg/kg/day, or 300 to 600 μg/day, or 6 mg/dose.
20. The method of claim 1 wherein the granulopoiesis stimulating factor is given intravenously or subcutaneously.